Unknown EARLY_PHASE1 INTERVENTIONAL 2-arm NCT03571100

Comfort and Antimicrobial Efficacy of Chlorhexidine vs Betadine for Intravitreal Injections

Patient Comfort and Antimicrobial Efficacy With Aqueous Chlorhexidine Versus Povidine-Iodine (Betadine) as Ocular Surface Disinfectant Prior to Intravitreal Injection

Sponsor: MidAtlantic Retina

Conditions Age-related Macular Degeneration Diabetic Vascular Diseases Proliferative Retinopathy Retina Vein Occlusion

Interventions Chlorhexidine Povidine-Iodine

Updated 5 times since 2018 Last updated: Jun 25, 2018 Started: May 7, 2018 Primary completion: May 6, 2019 Completion: May 6, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03571100, this EARLY_PHASE1 trial focuses on Age-related Macular Degeneration and Diabetic Vascular Diseases and remains ongoing. Sponsored by MidAtlantic Retina, it has been updated 5 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown EARLY_PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status EARLY_PHASE1
Jul 2020 — Jan 2021 [monthly]

Unknown Status EARLY_PHASE1

Status: Recruiting → Unknown Status
Jul 2018 — Jul 2020 [monthly]

Recruiting EARLY_PHASE1

First recorded

May 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MidAtlantic Retina

Data source: Wills Eye

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Philadelphia, United States